GlassScriptPhysician profile
Melissa M Ott
NPI 1396873063
$4,322.31
in general payments reported to CMS, 2019-2025
26 companies · $1,173 in 2025
The $1,173 reported for 2025 was more than what 83% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $459 · 2022: $598 · 2023: $1,232 · 2024: $859 · 2025: $1,173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,265.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $674.77 | 2022-2025 | |
| Axsome Therapeutics, INC. | $426.50 | 2022-2025 | Auvelity, Sunosi |
| Corium, LLC | $413.02 | 2023-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $375.32 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $286.79 | 2021-2025 | Trintellix |
| Alkermes, INC. | $273.66 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $272.21 | 2021-2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $249.57 | 2021-2025 | Hetlioz, Fanapt |
| Janssen Pharmaceuticals, INC | $240.49 | 2023-2025 | Spravato |
| Neurocrine Biosciences, INC. | $192.43 | 2023-2025 | Ingrezza |
| Lundbeck LLC | $153.01 | 2021-2025 | Rexulti, Brintellix |
| Eisai INC. | $140.75 | 2021 | |
| Tris Pharma INC | $103.47 | 2023-2025 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $82.41 | 2021-2025 | Qelbree, Qelbree |
| Bausch Health US, LLC | $76.47 | 2021-2024 | Aplenzin |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $76.06 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $50.87 | 2024 | Austedo Xr |
| Jazz Pharmaceuticals INC. | $40.56 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $39.03 | 2023 | Jornay Pm |
| Amgen INC. | $37.14 | 2022 | |
| Tempus Ai, INC | $29.32 | 2024 | |
| Harmony Biosciences LLC | $25.05 | 2025 | |
| Noven Therapeutics, LLC | $19.49 | 2024 | Xelstrym, Secuado |
| Owp Pharmaceuticals, INC. | $17.67 | 2022 | |
| Vertical Pharmaceuticals, LLC | $15.13 | 2025 | Relexxii |
| Alfasigma USA, INC. | $11.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Ott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.